Diligence memo · auto-generated · as of July 2, 2026
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Aegerion Pharmaceuticals, Inc. operates in Pharmaceuticals, based in BRIDGEWATER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Aegerion Pharmaceuticals, Inc. has raised $49M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2008-09-02.
Most recent recorded round closed around 2008-09-02.
Valuation (modeled)modeled
Provath models Aegerion Pharmaceuticals, Inc. at approximately $623M (range $38M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.73× the median modeled value of Series B Pharmaceuticals companies in 2007–2009 (9 peers) — value vs value, same stage and era. Within the normal band (73% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 17.8 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 81% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 83% of those peers.
Closest niche peers: Glycomimetics Inc, Avid Radiopharmaceuticals, Inc., Virdante Pharmaceuticals, Inc., Sirion Holdings, Inc., Viamet Pharmaceuticals Inc.
Peoplefiled
18 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.